Methylenedioxycyclopropylmethylamphetamine

MDCPM
Clinical data
Other names3,4-Methylenedioxy-N-cyclopropylmethylamphetamine
Routes of
administration
Oral[1]
ATC code
  • None
Pharmacokinetic data
Duration of actionUnknown[1]
Identifiers
  • N-(cyclopropylmethyl)-1-(2H-1,3-benzodioxol-5-yl)propan-2-amine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC14H19NO2
Molar mass233.311 g·mol−1
3D model (JSmol)
  • C3OC1C(C=CC(=C1)CC(C)NCC2CC2)O3
  • InChI=1S/C14H19NO2/c1-10(15-8-11-2-3-11)6-12-4-5-13-14(7-12)17-9-16-13/h4-5,7,10-11,15H,2-3,6,8-9H2,1H3 N
  • Key:AEIQNPMGFQNZNV-UHFFFAOYSA-N N
 NY (what is this?)  (verify)

MDCPM, also known as 3,4-methylenedioxy-N-cyclopropylmethylamphetamine, is a drug. It is the N-cyclopropylmethyl derivative of MDMA.[1] MDCPM was synthesized by Alexander Shulgin;[1] it is also one of the compounds delineated in a patent by Horrom in 1972.[2] In his book PiHKAL (Phenethylamines i Have Known And Loved), the minimum dosage is listed as 10 mg, and the duration unknown.[1] MDCPM produces few to no effects.[1] Very little data exists about the pharmacological properties, metabolism, and toxicity of MDCPM.[1]

Society and culture

United Kingdom

This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.[3]

See also

References

  1. ^ a b c d e f g Shulgin, Alexander; Shulgin, Ann (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN 0-9630096-0-5. OCLC 25627628.
  2. ^ U.S. patent 3,689,504
  3. ^ "UK Misuse of Drugs act 2001 Amendment summary". Isomer Design. Archived from the original on 22 October 2017. Retrieved 12 March 2014.